Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

369 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients.
Akashi-Tanaka S, Shimizu C, Ando M, Shibata T, Katsumata N, Kouno T, Terada K, Shien T, Yoshida M, Hojo T, Kinoshita T, Fujiwara Y, Yoshimura K. Akashi-Tanaka S, et al. Among authors: katsumata n. Breast. 2009 Jun;18(3):171-4. doi: 10.1016/j.breast.2009.03.005. Epub 2009 May 2. Breast. 2009. PMID: 19410462 Free article. Clinical Trial.
Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy.
Yonemori K, Katsumata N, Kaneko M, Uno H, Matsumoto K, Kouno T, Shimizu C, Ando M, Takeuchi M, Fujiwara Y. Yonemori K, et al. Among authors: katsumata n. Breast Cancer Res Treat. 2007 Jul;103(3):313-8. doi: 10.1007/s10549-006-9384-8. Epub 2006 Oct 25. Breast Cancer Res Treat. 2007. PMID: 17063267
Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome.
Shien T, Shimizu C, Seki K, Shibata T, Hojo T, Ando M, Kohno T, Katsumata N, Akashi-Tanaka S, Kinoshita T, Fujiwara Y. Shien T, et al. Among authors: katsumata n. Breast Cancer Res Treat. 2009 Jan;113(2):307-13. doi: 10.1007/s10549-008-9935-2. Epub 2008 Feb 20. Breast Cancer Res Treat. 2009. PMID: 18286370
Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy.
Yonemori K, Tsuta K, Shimizu C, Hatanaka Y, Hashizume K, Ono M, Kouno T, Ando M, Tamura K, Katsumata N, Hasegawa T, Kinoshita T, Fujiwara Y. Yonemori K, et al. Among authors: katsumata n. Med Oncol. 2009;26(3):344-9. doi: 10.1007/s12032-008-9127-2. Epub 2008 Nov 18. Med Oncol. 2009. PMID: 19016009
Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, Hirata T, Yonemori K, Ando M, Tamura K, Katsumata N, Kinoshita T, Takiguchi Y, Tanzawa H, Fujiwara Y. Ono M, et al. Among authors: katsumata n. Breast Cancer Res Treat. 2012 Apr;132(3):793-805. doi: 10.1007/s10549-011-1554-7. Epub 2011 May 12. Breast Cancer Res Treat. 2012. PMID: 21562709
FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer.
Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, Kouno T, Katsumata N, Ando M, Aogi K, Koizumi F, Nishio K, Fujiwara Y. Tamura K, et al. Among authors: katsumata n. Ann Oncol. 2011 Jun;22(6):1302-1307. doi: 10.1093/annonc/mdq585. Epub 2010 Nov 25. Ann Oncol. 2011. PMID: 21109570 Free article. Clinical Trial.
369 results